サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1795178

経粘膜ドラッグデリバリーシステムの世界市場

Transmucosal Drug Delivery Systems

出版日
ページ情報
英文 268 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
経粘膜ドラッグデリバリーシステムの世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

経粘膜ドラッグデリバリーシステムの世界市場は2030年までに1,114億米ドルに到達

2024年に826億米ドルと推定される経粘膜ドラッグデリバリーシステムの世界市場は、分析期間2024-2030年にCAGR 5.1%で成長し、2030年には1,114億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである鼻呼吸器システムは、CAGR 6.1％を記録し、分析期間終了までに653億米ドルに達すると予測されます。バッカル＆サブリンガルシステム分野の成長率は、分析期間中CAGR 3.6％と推定されます。

米国市場は225億米ドル、中国はCAGR 8.3％で成長すると予測

米国の経粘膜ドラッグデリバリーシステム市場は2024年に225億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに224億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と5.1%と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界の経粘膜ドラッグデリバリーシステム市場- 主要動向と促進要因まとめ

経粘膜ルートは薬剤投与にどのような革命をもたらすか？

経粘膜ドラッグデリバリーシステム（TDDS）は、頬、舌下、鼻、直腸、膣組織などの粘膜を活用し、消化管や初回通過肝代謝をバイパスして、薬剤を直接全身循環に投与します。これにより、オピオイドや制吐剤からホルモン剤や生物学的製剤に至るまで、幅広い治療薬の迅速な作用発現とバイオアベイラビリティの向上が可能となります。これらのシステムは、意識のない患者、吐き気のある患者、嚥下障害のある患者にとって特に有用であり、救急医療と慢性疾患管理の両方において重要なツールとなります。

TDDSの背後にある科学には、粘膜バリアを越えて浸透を高めるための綿密な製剤設計が含まれます。粘接着性ポリマー、浸透促進剤、ナノキャリアーなどの進歩により、薬物の滞留時間と吸収率は著しく改善されています。フィルム、パッチ、ロゼンジ、ゲルなどのフォームファクターは、放出制御と患者の利便性のために最適化されています。組織透過性、pH、酵素活性に応じてこれらの製剤をカスタマイズすることは、経粘膜デリバリーの複雑さと治療の多様性を強調しています。

有効性と患者のコンプライアンスを高める技術革新とは？

最近の製剤科学の飛躍的進歩により、ナノ粒子、リポソーム、ミセルをTDDSに組み込むことが可能になり、薬物の安定性と標的特異性が向上しました。これは、ペプチドやモノクローナル抗体のような壊れやすい分子の送達において特に有用です。経粘膜システムはまた、時間的にプログラムされた薬物放出や正確な投与が可能なデバイスを作り出す微細加工技術からも恩恵を受けています。センサーを組み込んだスマートパッチは、ドラッグデリバリーの動態をモニターし、特に老人や小児集団の服薬アドヒアランスを確保することができます。

さらに、針を使わない送達の動向は、痛みに敏感な市場や自己投与市場において、こうしたシステムの需要を加速させています。これは特に、糖尿病、片頭痛、ホルモン補充などの治療において顕著であり、定期的な注射が頬や鼻からのアプリケーションに置き換えられています。さらに、デジタルヘルスの統合により遠隔モニタリングやデータ収集が可能になり、医師の監視や患者の関与が高まっています。

経粘膜システムはどこに大きなインパクトを与えているか？

疼痛管理やホルモン療法にとどまらず、TDDSは腫瘍学、神経学、感染症においてますます重要な役割を果たしています。吐き気や嚥下障害をしばしば経験するがん患者は、制吐剤や鎮痛剤の舌下投与から利益を得ています。神経学では、経粘膜システムが発作や片頭痛の迅速なコントロールに使用されています。ベンゾジアゼピン系薬剤やトリプタン系薬剤の経鼻製剤は、その速効性と使いやすさから広く臨床に受け入れられています。

経粘膜システムの採用は、インフルエンザ、COVID-19、その他の病原体に対する針を使わない経鼻ワクチンの研究が進むにつれて、世界のワクチン接種プログラムでも拡大しています。ヘルスケアのインフラが限られている地域では、こうしたシステムによってコンプライアンスと配布を改善することができます。獣医療もまた拡大するフロンティアであり、ペットや家畜のために頬や鼻からのドラッグデリバリーが人気を集めています。

経粘膜ドラッグデリバリーシステム市場の成長はいくつかの要因によって牽引されている...

市場の拡大には、非侵襲的で患者に優しいドラッグデリバリーシステムに対する需要の高まりが寄与しています。てんかん発作、片頭痛、急性疼痛など、迅速な薬物作用を必要とする病態の有病率の上昇が、経粘膜的選択肢の取り込みを促進しています。生体接着性ポリマー、ナノ粒子ベースの製剤、プログラム可能な放出メカニズムなどの技術革新により、ドラッグの効能とデリバリーの精度が向上しています。さらに、製薬会社は治療の差別化と特許ライフサイクルの延長のため、経粘膜投与ルートに多額の投資を行っています。在宅ヘルスケアでのTDDSの採用、デジタルモニタリングソリューション、注射針を使わないワクチン接種キャンペーンは、先進国市場と新興国市場の両方で代替ドラッグデリバリー法に対する規制当局の支援が増加していることと同様に、成長をさらに加速させています。

セグメント

システム（鼻呼吸システム、頬舌下システム、膣システム）;エンドユース（ヘルスケア施設エンドユース、在宅医療施設エンドユース）

調査対象企業の例

  • 3M
  • Acrux Limited
  • ALZA Corporation
  • Antares Pharma
  • Aveva Drug Delivery Systems
  • Corium International
  • Cure Pharmaceutical
  • DURECT Corporation
  • Generex Biotechnology
  • IntelGenx Technologies Corp
  • Jazz Pharmaceuticals plc
  • Novartis AG
  • NAL Pharma
  • Pfizer Inc.
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Viatris
  • ZIM Laboratories Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38245

Global Transmucosal Drug Delivery Systems Market to Reach US$111.4 Billion by 2030

The global market for Transmucosal Drug Delivery Systems estimated at US$82.6 Billion in the year 2024, is expected to reach US$111.4 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Nasopulmonary System, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$65.3 Billion by the end of the analysis period. Growth in the Buccal & Sublingual System segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.5 Billion While China is Forecast to Grow at 8.3% CAGR

The Transmucosal Drug Delivery Systems market in the U.S. is estimated at US$22.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.4 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Transmucosal Drug Delivery Systems Market - Key Trends & Drivers Summarized

How Are Transmucosal Routes Revolutionizing Drug Administration?

Transmucosal drug delivery systems (TDDS) leverage mucous membranes such as buccal, sublingual, nasal, rectal, and vaginal tissues to administer drugs directly into the systemic circulation, bypassing the gastrointestinal tract and first-pass hepatic metabolism. This enables rapid onset of action and improved bioavailability for a wide range of therapeutic agents, from opioids and antiemetics to hormones and biologics. These systems are particularly valuable for patients who are unconscious, nauseated, or unable to swallow, making them a critical tool in both emergency care and chronic disease management.

The science behind TDDS involves meticulous formulation engineering to enhance permeation across mucosal barriers. Advances in mucoadhesive polymers, permeation enhancers, and nanocarriers have significantly improved drug residence time and absorption rates. Form factors such as films, patches, lozenges, and gels are being optimized for controlled release and patient convenience. The customization of these formulations according to tissue permeability, pH, and enzymatic activity underscores the complexity and therapeutic versatility of transmucosal delivery.

What Technological Innovations Are Enhancing Efficacy and Patient Compliance?

Recent breakthroughs in formulation science have enabled the incorporation of nanoparticles, liposomes, and micelles into TDDS to increase drug stability and target specificity. This is especially valuable in the delivery of fragile molecules such as peptides and monoclonal antibodies. Transmucosal systems are also benefiting from microfabrication technologies that create devices capable of time-programmed drug release and precise dosing. Smart patches embedded with sensors can monitor drug delivery kinetics and ensure adherence, especially in geriatric and pediatric populations.

Additionally, the trend towards needle-free delivery is accelerating demand for these systems in pain-sensitive and self-administration markets. This has been particularly evident in therapies for diabetes, migraines, and hormone replacement, where regular injections are being substituted by buccal or nasal applications. Moreover, digital health integration is enabling remote monitoring and data collection, increasing physician oversight and patient engagement.

Where Are Transmucosal Systems Making the Biggest Impact?

Beyond pain management and hormone therapy, TDDS are playing an increasingly vital role in oncology, neurology, and infectious diseases. Cancer patients, often experiencing nausea and dysphagia, benefit from sublingual delivery of antiemetics and analgesics. In neurology, transmucosal systems are being used for rapid control of seizures and migraines. Nasal formulations of benzodiazepines and triptans have found wide clinical acceptance due to their rapid onset and ease of use.

The adoption of transmucosal systems is also growing in global vaccination programs, as researchers explore needle-free nasal vaccines for influenza, COVID-19, and other pathogens. In regions with limited healthcare infrastructure, these systems can improve compliance and distribution. Veterinary medicine is another expanding frontier, with buccal and nasal drug delivery gaining traction for pets and livestock.

The Growth in the Transmucosal Drug Delivery Systems Market Is Driven by Several Factors…

The market’s expansion is fueled by increasing demand for non-invasive, patient-friendly drug delivery systems, especially among geriatric, pediatric, and chronic care populations. The rising prevalence of conditions requiring rapid drug action-such as epileptic seizures, migraines, and acute pain-is catalyzing the uptake of transmucosal options. Technological innovations in bioadhesive polymers, nanoparticle-based formulations, and programmable release mechanisms are enhancing drug efficacy and delivery precision. Furthermore, pharmaceutical companies are investing heavily in transmucosal routes to differentiate therapies and extend patent lifecycles. The adoption of TDDS in home healthcare settings, digital monitoring solutions, and needle-free vaccination campaigns is further amplifying growth, as is the increasing regulatory support for alternative drug delivery methods in both developed and emerging markets.

SCOPE OF STUDY:

The report analyzes the Transmucosal Drug Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

System (Nasopulmonary System, Buccal & Sublingual System, Vaginal System); End-Use (Healthcare Facilities End-Use, Homecare Settings End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • 3M
  • Acrux Limited
  • ALZA Corporation
  • Antares Pharma
  • Aveva Drug Delivery Systems
  • Corium International
  • Cure Pharmaceutical
  • DURECT Corporation
  • Generex Biotechnology
  • IntelGenx Technologies Corp
  • Jazz Pharmaceuticals plc
  • Novartis AG
  • NAL Pharma
  • Pfizer Inc.
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Viatris
  • ZIM Laboratories Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Transmucosal Drug Delivery Systems - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Preference for Non-Invasive, Rapid-Onset Drug Delivery Supports Growth of Transmucosal Systems
    • Increased Demand for Buccal and Sublingual Routes in Pain Management and Emergency Care Boosts Adoption
    • Growth in CNS and Hormone Therapies Drives Development of Nasal and Oral Mucosal Formulations
    • Technological Advancements in Mucoadhesive Films and Sprays Enhance Bioavailability
    • Expansion of Transmucosal Delivery in Pediatric and Geriatric Care Improves Compliance
    • Faster Onset Compared to Oral and Injectable Forms Supports Emergency Therapeutic Use
    • Improved Taste Masking and Stability Features Enhance Consumer Acceptance
    • Growth in Self-Administered Drug Formats Drives At-Home Healthcare Trends
    • Increased R&D in Peptide and Biologic Delivery via Mucosal Pathways Expands Pipeline Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Transmucosal Drug Delivery Systems Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nasopulmonary System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nasopulmonary System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nasopulmonary System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Buccal & Sublingual System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Buccal & Sublingual System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Buccal & Sublingual System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaginal System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaginal System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaginal System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Healthcare Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Homecare Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION